Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Recruiting 29Completed 27Unknown 24Not yet recruiting 9Active not recruiting 8Withdrawn 5Terminated 4

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 2

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

pertuzumab 1cc-486 1Trastuzumab 1Sulindac 1Magnetic Resonance Spectroscopy 1Epirubicin 1Docetaxel 1Cytarabine 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Pathologic Complete Response × Clear all
NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Yale University

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Cedars-Sinai Medical Center

Phase 2 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01843179 2017-02-17

Sulindac for Patients With AML

Massachusetts General Hospital

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01956513 2013-10-08

ADC

Centre Jean Perrin

Phase NA Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡